Target intelligence / Profile preview

E3 ubiquitin-protein ligase Deltex-1 (DTX1)

Target
DTX1
Molecular classification
Enzyme, E3 ubiquitin ligase, RING-type E3 ligase
01

Overview

E3 ubiquitin-protein ligase Deltex-1 (DTX1) is a member of the Deltex protein family and serves as an E3 ubiquitin ligase, a key enzyme responsible for transferring ubiquitin to specific substrates during protein ubiquitination. DTX1 is highly conserved evolutionarily and is expressed in both the cytoplasm and nucleus. DTX1 is a central regulator of the Notch signaling pathway in a variety of cell types, including immune cells where it modulates T and B cell development, apoptosis, and immune tolerance. DTX1 interacts with multiple signaling pathways—including PI3K/AKT and MAPK—and with downstream targets such as c-FLIP, MEKK1, HIF-1α, and transcription factors like HES1 and NFAT. Dysregulation or mutation of DTX1 has been linked to several malignancies, especially B cell lymphomas, where it may act as either a tumor suppressor or oncogene depending on cellular context. Its precise physiological and pathological mechanisms continue to be areas of active research, and it is being explored as a potential diagnostic and therapeutic target in cancer and immune-related disorders

Other names
Deltex1hDTX1hDx-1RNF140protein deltex-1RING-type E3 ubiquitin transferase DTX1deltex homolog 1E3 ubiquitin ligaseDTX1_HUMAN
02

Mechanism of action

No drugs directly target DTX1 in clinical use; inhibitors would theoretically modulate protein ubiquitination and Notch signaling, with downstream effects on cell differentiation, apoptosis, and immune responses

03

Biological functions

Ubiquitination (post-translational modification of proteins)Regulation of Notch signaling pathwayRegulation of cell differentiationRegulation of cell growth and proliferationApoptosisImmune response modulation (especially in T and B lymphocytes)Regulation of transcription factors
04

Disease associations

Cancer (oncogenic and tumor suppressor roles reported)Immune disordersLymphoid malignancies (including B cell malignancies such as splenic marginal zone lymphoma)Other (potential roles in neurological development and disease due to Notch regulation)
05

Safety considerations

Potential impacts on immune function and normal differentiationPotential for dual oncogenic or tumor suppressor activity depending on cellular context, signaling network, and cancer type
06

Interacting drugs

None are documented as clinically approved or direct DTX1-targeting agents as of the latest literature
07

Biomarkers

As of current knowledge, DTX1 expression and/or genetic abnormalities are being investigated as biomarkers in certain lymphomas and cancers, particularly marginal zone B cell malignancies

Beyond the preview

Go deeper on E3 ubiquitin-protein ligase Deltex-1 (DTX1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on E3 ubiquitin-protein ligase Deltex-1 (DTX1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call